GLP-1 Receptor Agonist Market Trends, Share, Demand, Size, Competition and Future Outlook
GLP-1 Receptor Agonist Market Growth, Size, Trends Analysis- By Product, By Application, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Oct-2024 | Report ID: PHAR2415 | Pages: 1 - 243 | Formats*: |
| Category : Pharmaceutical | |||
Global GLP-1 Receptor Agonist Market Introduction and Overview
According to SPER Market Research, the Global GLP-1 Receptor Agonist Market is estimated to reach USD 266.54 billion by 2033 with a CAGR of 21.9%.
The report includes an in-depth analysis of the Global GLP-1 Receptor Agonist Market, including market size and trends, product mix, applications, and supplier analysis. A class of drugs known as GLP-1 receptor agonists is mostly used to treat type 2 diabetes and, more recently, obesity. They function similarly to glucagon-like peptide-1 (GLP-1), a hormone that inhibits glucagon release, slows stomach emptying, increases feelings of fullness, and raises insulin secretion in response to meals. These medications aid in better blood sugar regulation and can promote weight loss by improving insulin sensitivity and controlling hunger. Liraglutide and semaglutide are common examples that have also demonstrated cardiovascular benefits.
- In February 2024, Eli Lilly and Company announced that if Mounjaro, their extremely effective diabetes drug and obesity treatment, survives a continuing regulatory review, it might be introduced in India as early as the following year. This product should have a favorable effect on the growth of the Indian market.
- Even though it is having trouble meeting demand in its current territories, Novo Nordisk A/S announced in November 2023 that it would offer its very successful anti-obesity medication, Wegovy, in Japan on February 22. This would be the company's first Asian launch.
Market Opportunities and Challenges
Opportunities- The market is expected to be driven by the introduction of new GLP-1 receptor agonist pharmaceuticals, a robust pipeline of products for diabetes and obesity applications, and the high efficacy of these medications. To treat patients with type 2 diabetes, obesity, and cardio-metabolic disorders, Eccogen and AstraZeneca, for example, inked an exclusive licensing agreement in November 2023 for ECC5004, an experimental oral GLP-1 receptor agonist. According to the initial findings of a phase I trial, ECC5004 has a unique clinical profile, high tolerability, and encouraging decreases in body weight and glucose at all tested dose levels when compared to a placebo.
Challenges- Many challenges could hinder the market's expansion and accessibility for GLP-1 receptor agonists. Patient access is frequently hampered by the high cost of these drugs, particularly in areas with less extensive healthcare infrastructures. Concerns have also been raised regarding adverse effects, like gastrointestinal problems, which may discourage patients from following their treatment plan. The situation is made more challenging by competition from alternative treatments for diabetes and obesity, such as non-pharmacological approaches and newer drugs. The approval procedure for novel formulations might also be slowed by regulatory obstacles and the requirement for substantial clinical data to prove long-term safety and efficacy.
Market Competitive Landscape
The Global GLP-1 Receptor Agonist Market is highly consolidated. Some of the market key players are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product, By Application, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi. |
COVID-19 Impact on Global GLP-1 Receptor Agonist Market
The global market for GLP-1 receptor agonists was greatly impacted by the COVID-19 epidemic in a number of ways. At first, the interruption of medical services resulted in fewer patient visits and postponed diabetes and obesity diagnoses, which in turn reduced the number of new prescriptions for these drugs. GLP-1 receptor agonist availability was also impacted by supply chain disruptions, leading to shortages in certain areas. On the other hand, because those with diabetes were more vulnerable to COVID-19, the pandemic raised awareness of metabolic health and brought attention to the need to manage these disorders.
Key Target Audience:
- Healthcare Providers
- Patients with Type 2 Diabetes
- Obesity Patients
- Endocrinologists
- Diabetes Educators
- Pharmacists
- Insurance Companies
- Pharmaceutical Companies
Our in-depth analysis of the Global GLP-1 Receptor Agonist Market includes the following segments:
| By Product: | |
| By Application: | |
| By Route of Administration: | |
| By Distribution Channel: |
Key Topics Covered in the Report:
- Global GLP-1 Receptor Agonist Market Size (FY’2024-FY’2033)
- Overview of Global GLP-1 Receptor Agonist Market
- Segmentation of Global GLP-1 Receptor Agonist Market By Product (Ozempic,k Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other)
- Segmentation of Global GLP-1 Receptor Agonist Market By Application (Type 2 Diabetes Mellitus, Obesity)
- Segmentation of Global GLP-1 Receptor Agonist Market By Route of Administration (Parenteral, Oral)
- Segmentation of Global GLP-1 Receptor Agonist Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- Statistical Snap of Global GLP-1 Receptor Agonist Market
- Expansion Analysis of Global GLP-1 Receptor Agonist Market
- Problems and Obstacles in Global GLP-1 Receptor Agonist Market
- Competitive Landscape in the Global GLP-1 Receptor Agonist Market
- Impact of COVID-19 and Demonetization on Global GLP-1 Receptor Agonist Market
- Details on Current Investment in Global GLP-1 Receptor Agonist Market
- Competitive Analysis of Global GLP-1 Receptor Agonist Market
- Prominent Players in the Global GLP-1 Receptor Agonist Market
- SWOT Analysis of Global GLP-1 Receptor Agonist Market
- Global GLP-1 Receptor Agonist Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global GLP-1 Receptor Agonist Market.
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global GLP-1 Receptor Agonist Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global GLP-1 Receptor Agonist Market
7. Global GLP-1 Receptor Agonist Market, By Product (USD Million) 2020-2033
7.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2020-20267.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2027-20337.3. Ozempic7.4. Trulicity7.5. Mounjaro7.6. Wegovy7.7. Rybelsus7.8. Saxenda7.9. Victoza7.10. Zepbound7.11. Other Products
8. Global GLP-1 Receptor Agonist Market, By Application (USD Million) 2020-2033
8.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2020-20268.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2027-20338.3. Type 2 Diabetes Mellitus8.4. Obesity
9. Global GLP-1 Receptor Agonist Market, By Route of Administration (USD Million) 2020-2033
9.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2020-20269.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2027-20339.3. Parenteral9.4. Oral
10. Global GLP-1 Receptor Agonist Market, By Distribution Channel (USD Million) 2020-2033
10.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2020-202610.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2027-203310.3. Hospital Pharmacies10.4. Retail Pharmacies10.5. Online Pharmacies
11. Global GLP-1 Receptor Agonist Market Forecast, 2020-2033 (USD Million)
11.1. Global GLP-1 Receptor Agonist Market Size and Market Share
12. Global GLP-1 Receptor Agonist Market, By Region, 2020-2033 (USD Million)
12.1. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2020-2026)12.2. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2027-2033)12.3. Asia-Pacific12.3.1. Australia12.3.2. China12.3.3. India12.3.4. Japan12.3.5. South Korea12.3.6. Rest of Asia-Pacific12.4. Europe12.4.1. France12.4.2. Germany12.4.3. Italy12.4.4. Spain12.4.5. United Kingdom12.4.6. Rest of Europe12.5. Middle East and Africa12.5.1. Kingdom of Saudi Arabia12.5.2. United Arab Emirates12.5.3. Qatar12.5.4. South Africa12.5.5. Egypt12.5.6. Morocco12.5.7. Nigeria12.5.8. Rest of Middle-East and Africa12.6. North America12.6.1. Canada12.6.2. Mexico12.6.3. United States12.7. Latin America12.7.1. Argentina12.7.2. Brazil12.7.3. Rest of Latin America
13. Company Profile
13.1. Eli Lilly and Company13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. Sanofi13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Novo Nordisk A/S13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. AstraZeneca13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
GLP-1 Receptor Agonist Market is projected to reach USD 266.54 billion by 2033, growing at a CAGR of 21.9% during the forecast period.
GLP-1 Receptor Agonist Market grew in Market size from 2024. The Market is expected to reach USD 266.54 billion by 2033, at a CAGR of 21.9% during the forecast period.
GLP-1 Receptor Agonist Market CAGR of 21.9% during the forecast period.
You can get the sample pages by clicking the link - Click Here
GLP-1 Receptor Agonist Market size is USD 266.54 billion from 2024 to 2033.
GLP-1 Receptor Agonist Market is covered By Product, By Application, By Route of Administration and By Distribution Channel
The North America is anticipated to have the highest Market share in the GLP-1 Receptor Agonist Market.
The Key players in the Market include Companies Covered Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
